ArticlemedRxiv : the preprint server for health sciences2025
A Phase 0 Window of Opportunity Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Patients with Recurrent Gliomas.
Eric C Burton et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.